PROCEPT BioRobotics Corporation
HealthcareNASDAQ:PRCT · NASDAQ Global Market
-$1.99 today
Vol 1.38M · Avg 1.37M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$322.0M of revenue converted into -$102.5M of net income for the selected period. Gross margin is 62.9% and net margin is -31.9%, showing how much revenue survives after costs and taxes. EPS is $-1.82, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $308.1M +37.2% | $224.5M +64.8% | $136.2M +81.6% | $75.0M +117.6% | $34.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $111.8M +28.0% | $87.4M +34.2% | $65.1M +71.7% | $37.9M +103.8% | $18.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $196.2M +43.1% | $137.1M +93.0% | $71.0M +91.6% | $37.1M +133.8% | $15.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 63.7% +2.6pp | 61.1% +8.9pp | 52.2% +2.7pp | 49.4% +3.4pp | 46.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $71.3M +14.4% | $62.3M +28.6% | $48.4M +67.2% | $29.0M +52.6% | $19.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $228.8M +33.5% | $171.4M +30.1% | $131.8M +48.3% | $88.8M +74.0% | $51.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $300.1M +28.4% | $233.7M +29.7% | $180.2M +53.0% | $117.8M +68.2% | $70.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.4M +22.1% | $5.2M +37.5% | $3.8M +34.0% | $2.8M -14.5% | $3.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$85.4M -4.2% | -$82.0M +16.4% | -$98.1M -24.0% | -$79.1M -56.0% | -$50.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -27.7% +8.8pp | -36.5% +35.5pp | -72.0% +33.5pp | -105.5% +41.6pp | -147.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$103.9M -7.5% | -$96.6M +11.5% | -$109.2M -35.2% | -$80.7M -49.0% | -$54.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -33.7% +9.3pp | -43.0% +37.1pp | -80.2% +27.5pp | -107.6% +49.5pp | -157.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $12.2M +12.2% | $10.9M +44.3% | $7.6M +202.4% | $2.5M +3185.5% | $76.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.6M -14.3% | $4.2M +4.7% | $4.0M -22.9% | $5.2M -10.8% | $5.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $8.5M +63.0% | $5.2M +58.9% | $3.3M +150.9% | -$6.4M -13.0% | -$5.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$95.4M -4.3% | -$91.4M +13.7% | -$105.9M -21.5% | -$87.2M -45.6% | -$59.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -31.0% +9.8pp | -40.7% +37.0pp | -77.8% +38.4pp | -116.2% +57.4pp | -173.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $190.0K | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$95.6M -4.5% | -$91.4M +13.7% | -$105.9M -21.5% | -$87.2M -45.6% | -$59.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -31.0% +9.7pp | -40.7% +37.0pp | -77.8% +38.4pp | -116.2% +57.4pp | -173.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +1.7% | -$2 +21.9% | -$2 -14.3% | -$2 -43.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +1.7% | -$2 +21.9% | -$2 -14.3% | -$2 -43.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $55.5M +6.6% | $52.1M +10.3% | $47.3M +6.4% | $44.4M +1.6% | $43.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $55.5M +6.6% | $52.1M +10.3% | $47.3M +6.4% | $44.4M +1.6% | $43.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.73B
Clover Health Investments, Corp.
NASDAQ:CLOV
$2.45B
Mesoblast Limited
NASDAQ:MESO
$1.79B
Inspire Medical Systems, Inc.
NYSE:INSP
$1.23B
Artivion, Inc.
NYSE:AORT
$975.72M
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
BGM Group Ltd.
NASDAQ:BGM
$75.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRCT generate?
PROCEPT BioRobotics Corporation (PRCT) reported $308.05M of revenue in fiscal 2025.
Is PRCT profitable?
PROCEPT BioRobotics Corporation (PRCT) reported -$95,572,000.00 of net income, with a net margin of -31.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.